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A B S T R A C T
Genital infection with high-risk human papillomavirus (HR HPV) associates with increased risk of developing pre-
cancerous lesions, such as cervical intraepithelial neoplasia (CIN). The objective of this pilot study conducted in north-
-east Croatia was to determine the prevalence of HPV genital infection in women with abnormal cervical cytology and to
determine its association with their age and HPV genotype(s). From March 2009 to December 2011, cervical swabs from
100 women were analysed for HR HPV infection (AMPLICOR HPV Test, Roche Diagnostics) and genotyped for high
risk (HR), intermediate (IR) and low risk (LR) HPVs (Linear Array HPV Genotyping Test, Roche Diagnostics). The most
prevalent HR genotypes in women with CIN were HPV 16 (27.6%), HPV 31 (11.8%), HPV 51 and HPV 52 (10.2% each).
The most prevalent IR genotypes were HPV 66 (30%) and HPV 62 (23.3%). The most prevalent LR genotype was HPV 6
(20.3%). Women between 21 and 25 years of age showed the highest rate of HPV infection (44.2%). Moreover, women
younger than 35 years showed a significant association (p<0.01) and positive correlation (r=0.67; p<0.05) between HR
HPV infection and CIN stages 1 and 2. Multiple HPV infections were found in almost half of the women. This is the first
study that analysed the prevalence of genital infection with HR/IR/LR HPVs in women with CIN from north-east Croa-
tia. Despite the preliminary nature of this pilot study, the lower prevalence of some HR HPVs (HPV18) and the higher
prevalence of other HR HPVs (HPVs 51, 52 and 31) may imply the necessity for the development of more targeted anti-
-HPV vaccines or other strategies for more efficient protection against oncogenic HPV infection in women from our region.
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Introduction
Genital infection with human papilloma virus (HPV)
is the most common sexually transmitted disease in
women. Due to its infection persistency and oncogenic
potential, infections with high risk HPV genotypes play a
crucial rule in the development of cervical lesions, ac-
counting for 43% to 53% of CIN-positive women in the
Western world. Although 70–90% of HPV infected women
clear their infections within one to two years through
natural immune process1,2, cervical cancer represents
the second most common female cancer worldwide. Elf-
gren et al. reported that 370,000 new cases and 190,000
deaths occur yearly in less developed countries1.
Since the last 30 years, cervical screenings by cytolog-
ical Papanicolaou (Pap) test and quadrivalent vaccina-
tions against the most oncogenic HPVs have decreased
the incidence of cervical cancer and its related cancers
such as vulvar and colorectal cancer. Early treatment of
HPV infection helps to prevent cervical cancer and de-
creases mortality3. Cross sectional studies across the
world showed that the prevalence of HPV infection var-
ies by age, country and race4,5. In Croatia, with its overall
incidence of 13.6 per 100,000, cervical carcinoma is the
second most common cancer in highly sexually active
25–40 year-old women5. Due to its skin-to-skin, vaginal,
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oral and sexual transmission and often asymptomatic na-
ture, HPV infection spreads easily among young popu-
lation1.
According to phylogenetic differences and relative
risk for HPV-related progression to cervical dysplasia,
HPV genotypes are classified into 3 subtypes:
HR HPV (high-risk HPV): 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 82, 73;
IR HPV (intermediate-risk HPV): 26, 40, 53, 54, 55,
61, 62, 64, 66, 67, 70, 83;
LR HPV (low risk HPV): 6, 11, 42, 43, 44, 81, 84,
CP6108.
The aims of this pilot study were to determine the dis-
tribution of HR/IR/LR HPV genotypes, their association
with age and CIN stages, and the age-related prevalence
of single and multiple HPV infections in women from
Osijek-Baranja County diagnosed with CIN.
Material and Methods
Study population
From March 2009 to December 2011, cervical swabs
from 100 symptomatic women were provided by gynecol-
ogist offices from the Osijek-Baranja County. Collection
of cervical specimens was performed according to the
AMPLICOR HPV test instructions (Roche Diagnostics,
Germany). All women were referred to our department
by their general practitioners or gynaecologists and the
information about their CIN was obtained from gynecol-
ogist’s questionnaires. All study participants gave in-
formed consent and the Ethics Committee of the Insti-
tute of Public Health of the Osijek-Baranja County
approved the study.
HR HPV detection
DNA was isolated using the High Pure PCR Template
Kit and analyzed for the presence of HR HPV by the
AMPLICOR HPV test (Roche Diagnostics, Germany) ac-
cording to the manufacturer’s instructions. DNA from
positive swab specimens was stored at –20 °C until subse-
quent HPV genotyping.
HR/IR/LR genotyping
The HR HPV positive cervical samples were geno-
typed by the Linear Array HPV Genotyping Test (Roche
Diagnostics). This test detects 37 high risk (HR), inter-
mediate risk (IR) and low risk (LR) HPV genotypes (HPV
6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54,
55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81,
82, 83, IS39 and CP6108). It is based on the Polymerase
Chain Reaction (PCR)-based amplification of polymor-
phic L1 region, hybridization to the HPV probes and
colorimetric visualisation. As internal control, test am-
plifies beta-globin gene to asses cellular adequacy, extrac-
tion and amplification for each processed specimen.
Statistical analysis
Women were classified according to their age (under
20, 21–25, 26–30, 31–35, 36–40 and above 40 years) and
Pap smear status (CIN1-3). Prevalence of HR/IR/LR
HPV genital infection and association with CIN stages
were analyzed by chi-square and Spearman’s correlation
rank tests (Figures 1, 2 and 3). The prevalence of multi-
ple and single HPV infections according to age was ana-
lyzed by Fisher exact test (Figure 4). Statistica 8.0 soft-
ware was used for all calculations (StatSoft).
Results
Prevalence of HR, IR and LR HPV genotypes
HPV 16 was the most prevalent HR HPV genotype
(27.6%), followed by HPVs 31 (11.8%), 51 and 52 (10.2%
each), 18 (7.1%), 39 (6.3%), 56 and 59 (5.5% each), 58
(4.7%), 33 (3.9%), 45 and 68 (2.4% each), 35 (1.6%), and
82 (0.8%). HPV 66 was the most prevalent IR HPV geno-
type (30%), followed by HPVs 62 (23.3%), 53 and 61
(16.7% each), and 54, 55, 70, and 83 (3.3 % each). HPV 6
was the most prevalent LR HPV genotype (20.3%), fol-
lowed by HPVs 42 and CP 6108 (25% each), and 81 and
84 (20% each) (results not shown).
HPV prevalence according to CIN and age
HR HPV infection significantly associated with CIN
stages 1 and 2 (p<0.01) as shown by the c2-test (Figure
1). Moreover, there was a positive correlation between
HR HPV cervical infections and CIN 1 and 2 (Spear-
man’s correlation coefficient r=0.67; p<0.05). On the
other hand, no significant association was detected be-
tween: i) HR HPV infection and CIN 3; ii) IR HPV geni-
tal infection and CIN stages 2 and 3; iii) LR HPV genital
infection and any CIN stage (Figures 2 and 3). Using the











































































Fig. 2. Distribution of IR HPV according to CIN.
Spearman’s rank test, no correlation was detected be-
tween genital infections with IR/LR HPVs and CIN.
CIN in women younger than 35 years showed a signif-
icant association with HR HPV infection (p<0.01). CIN
in women older than 36 did not significantly associated
with HR HPV. Moreover, women younger than 30 years
had a significantly higher prevalence of IR HPV infection
(p<0.01).
Prevalence of single and multiple HPV infections
according to age
Out of 100 women diagnosed with CIN, 57% of them
were infected with a single HPV genotype and 43% of
them with multiple HPV genotypes. Figure 4 shows that
single HPV infections were mostly prevalent in 26–30
and 21–25 year old women (15.2% and 14.1%, respec-
tively), followed by women between 30 and 35 years and
older than 40 (8.1% each), women younger than 20
(6.1%), and 36–40 years old women (5.1%).
Multiple HPV infections were most prevalent in 21–
25 year old women (19.2%) but less common in other age
categories. There, 8.1% of 31–35 year old women, 7.1% of
26–30 year old women, 6.1% of women younger than 20,
2% of women older than 40, and 1% of 36–40 year old




In this pilot study of 100 women with CIN from
north-east Croatia, the two most common high risk HPV
genotypes were HPVs 16 and 31 (28% and 12%, respec-
tively). Both genotypes significantly associated with CIN1
and CIN2 (p<0.01 each) but not with CIN3. The latter
may be due to the low number of study participants with
severe dysplasia (CIN3). Similar prevalence of HPV 16
and 31 was reported in two studies from Italy6 and
Spain3. The prevalence of HPV 31 in our study popula-
tion (12%) was however higher than in women with CIN
from Brazil7, Canada8,9, and the USA10 (10%, 3% and 7%,
respectively).
Contrary to the world-wide epidemiological studies11
and reports from Brazil7, Iran12, and the USA10 (46%,
12% and 13%, respectively), the prevalence of HPV 18 in
our study population was low (7.1%) but similar to some
European countries12–26. Although this difference in the
prevalence of HPV 18 may be caused not only by differ-
ent sensitivities of PCR-based tests used for HPV geno-
typing, but also due to different stages of cervical dyspla-
sia in tested study populations. Indeed, a clinical study
from northern Croatia (Istra) detected a higher preva-
lence of HPV 18 in women with invasive adenocarcinoma
and adenocarcinoma in situ14.
The prevalence of high risk HPV 52 in our study
(10.2%) was higher than in women with CIN from the
nearby regions such as Split-Dalmatia County13 and
neighbouring Slovenia15 (1.4% and 5%, respectively).
The prevalence of high risk HPV51 in our study (10.2 %)
was similar to that in women with CIN1 from Canada
(13%)16 and the USA (12%)17, higher than in Spain3 and
Brazil7 (7% and 3%, respectively) but lower than in
women from Italy (37%)4.
At this point, it remains unclear whether the afore-
-mentioned discrepancies in the prevalence of certain HR
HPVs reflect the »true« region- or race-specific differ-
ences and not just a consequence of different sensitivities
of HPV detection methodologies. We find nevertheless
interesting that the prevalence of oncogenic HPV 18 in
women with CIN from our County was lower than ex-
pected. On the other hand, some oncogenic HPVs (HPVs
31, 51 and 52) in our study population were more fre-
quent than in reports from other regions/countries. This
may suggest a need for a more specific anti-HPV vaccine
in order to achieve some protection against high grade
cervical disease although currently available quadriva-
lent vaccine shows cross protective effect on precancer-
ous lesions and carcinoma in situ caused by oncogenic
HPV types other than vaccine strains22.
IR HPV
The most prevalent intermediate risk HPV in our re-
gion was HPV 66 (30%), similarly to reports from Tan-
zania21 (16%), Spain3 (9%), and Canada23 (5%). However,
this genotype was not found in Italy6 and Slovenia15 and
was very low in women from the USA10 (1.1%). Whether
this difference is due to different hybridization specifi-
cities and/or cross-reactivity to other genotypes remains
to be elucidated. Since HPV 66 is often detected in symp-
tomatic women with multiple HPV infections but is
rarely found in women with cancer24,25 and single HPV66
infection, it may not be a strong contributing factor in





























































Fig. 4. Multiple and single HPV infections according to age.
the development of cervical cancer23. Other IR genotypes
that were observed in women from our study were HPVs
62, 53, and 61 (23%, 17%, 17%, respectively). Interest-
ingly, HPVs 62 and 61 were not detected in women from
Spain3. Finally, we found no significant association be-
tween IR HPV infection and CIN grades 2 and 3.
LR HPV
With a slight predominance of HPV6, the prevalence
of the most common LR HPVs (6, 42, CP1208, 81, 84) in
our study population was comparable (30%, 25%, 25%,
20%, 20%). A similar predominance of HPV6 was re-
ported in women with CIN from Brazil (24%)7. On the
contrary, a study from Tanzania21 reported a strong pre-
dominance of HPV 81 and 84 genotypes (28% each). As
expected, we detected no significant association between
LR HPV infection and CIN.
Age-specific distribution of HR HPV
in women with CIN
A recent Croatian study reported that 55–60% of
women younger than 30 with cervical dysplasia show a
significantly higher prevalence of HR HPV infection26,27.
We also observed a significant association between CIN
and HR HPV infection(s) in women younger than 35.
This may be due to more frequent and/or less protected
(no condom) sexual activity of younger women, inter-
course with uncircumcised men and history of herpes
simplex virus or Chlamydia infections28,29. For example,
Ljubojevi} et al. reported that the usage of oral contra-
ceptives associated with less frequent usage of condoms.
Similar tendency was reported for women with more
than 4 lifetime sexual partners and those whose partners
had more than 16 female partners26.
No association between HR HPV infection and CIN in
our study participants older than 36 may be explained by
their decreased sexual activity, lower number of sexual
partners and possible clearance of HR HPV infection(s).
HPV status and the number of lifetime sexual partners,
as well as choosing male partners who have previously
had less than 16 other female sexual partners were
strong predictors of CIN regression26.
Age-specific distribution of single and multiple
HPV infections in women with CIN
Similarly to the recent study of women from Osijek-
-Baranya County30, we also observed multiple HPV infec-
tions in our study participants. Five percent of cervical
swabs were infected with more than 5 different HPVs,
whereas 46% of swabs showed concurrent infections with
several HPV genotypes. The rate of multiple infections
was however lower than that in women with CIN from
the USA (66%)2,31. As expected, we also found that the
highest rate of multiple HPV infections occurred in wo-
men younger than 30. When compared to our study pop-
ulation, Danish women with CIN2/3 in the same age cat-
egory had a higher rate of multiple infection (30 vs.
61%)25.
There are several limitations to this study: i) low
number of cases with high grade cervical dysplasia (CIN2,
3) and CIS; ii) unknown medical history of previous geni-
tal infections; iii) disproportion between younger and
older study participants. Nevertheless, the results pre-
sented here are useful in designing future prospective
case-control studies and better prevention methods against
acquiring HR HPV infection.
Conclusion
This pilot study of 100 women with CIN from north-
-east Croatia showed that cervical HR HPV infections as-
sociated with CIN. The highest prevalence of multiple
HPV infection was detected in young women (21–25 year
old). HPV genotypes distribution (HPV16, HPV18, and
31) was very similar to distribution obtained by others.
Contrary, HR HPV52 prevalence in women with CINs
was significantly higher.
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RASPODJELA SPOLNIH LJUDSKIH PAPILOMAVIRUS GENOTIPOVA KOD @ENA
SA INTRAEPITENOM NEOPLAZIJOM GRLI]A MATERNICE (CIN)
S A @ E T A K
Spolna HPV infekcija, posebno s onkogenim visokorizi~nim ljudskim papiloma virusima (HR HPV prema engl. High
Risk Human Papillomavirus), se dovodi u svezu s pove}anim rizikom razvoja prekanceroznih promjena kao {to su
cervikalne intraepitelne neoplazije (CIN). Cilj ove pilot studije je utvrditi prevalenciju genitalnih HPV infekcija u `ena s
abnormalnim cervikalnim citolo{kim nalazom i njihovu povezanost sa `ivotnom dobi pacijentica i genotypom HPVa. Svi
uzorci testirani su na nazo~nost HR HPV uporabom AMPLICOR HPV testa (Roche Diagnostics) i genotipizirani upora-
bom Linear Array HPV Genotyping testa (Roche Diagnostics). Naju~estaliji HR HPv genotipovi u `ena s CIN su HPV
16 (27,6%), HPV 31 (11,8%), HPV 51 and 52 (10,2% svaki). U grupi srednjerizi~nih HPV-a (IR HPV) naju~estaliji su
HPV 66 (30%) i HPV 62 (23,3%) dok je u grupi niskorizi~nih HPV-a (LR HPV) naju~estaliji HPV 6 (20,3%). Najve}u
prevalenciju HPV infekcija imale su `ene izme|u 21 i 25 godina (44,2%). Nadalje, `ene mla|e od 35 godina imale su
zna~ajnu povezanost (p<0,01) i pozitivnu korelaciju (r=0,67; p<0,5) izme|u infekcija HR HPV i CIN 1 i 2. Multiple
infekcije dokazane su u skoro polovine ispitanica. Ovo je prvo istra`ivanje prevalencije genitalnih infekcija sa HR/IR/LR
HPV genotipovima kod `ena sa abnormalnim citolo{kim nalazom u Osje~ko-baranjskoj `upaniji. Usprkos preliminar-
noj prirodi ovog pilot-istra`ivanja, ni`a prevalencija nekih HR HPV genotipova (HPV18) koji su uklju~eni u dostupno
~etverovalentno cjepivo kao i vi{a prevalencija nekih drugih HR HPV (HPV51, 52 i 31) protiv kojih cjepivo pru`a djelo-
mi~nu unakrsnu za{titu upu}uju na potrebu za njegovom {irom primjenom ali i za razvijanjem djelotvornijih za{titnih
mjera protiv onkogenih HPV infekcija `ena u na{oj regiji.
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